|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||11.30 / 22.49|
In recent trading, shares of NanoString Technologies Inc have crossed above the average analyst 12-month target price of $20.60, changing hands for $20.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Investors eyeing a purchase of NanoString Technologies Inc stock, but cautious about paying the going market price of $16.51/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $15 strike, which has a bid at the time of this writing of $1.05.
More than 30 Abstracts Demonstrate the Value of the nCounter Platform for Disease Characterization, Translational Research and Diagnostic Applications in Cancer Research and Immuno-Oncology
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Revenue Growth Driven by Strong Consumable Pull-Through and Diagnostic Collaborations
nCounter-Based Technology Counts Protein Targets in the Spatial Context of Fixed, Slide-Mounted Tissues
Dr. Leroy Hood to serve as chief science officer for Providence
Record Revenue Driven by Installed Base Growth, Robust Consumable Pull-Through and Multiple Companion Diagnostic Collaborations
NanoString Eligible to Receive Up to $24 Million for Technology Access and Near-Term Milestones, Plus Development Funding and Undisclosed Downstream Payments
Hyb & Seq™ Chemistry Demonstrates High Accuracy With Simple Workflow Free of Library, Enzymes and Amplification
Prosigna One of Only Two Assays to Receive Strong Recommendation Together With High Rating of Evidence Quality